Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

In this multicenter, open-label, single-arm, Phase II study with Simon two-stage optimum design (NCT04361370), we investigate the efficacy and safety of triplet maintenance (olaparib, pembrolizumab, bevacizumab) in patients with platinum-sensitive recurrent ovarian cancer who are wild-type for BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yoo-Na, Park, Boram, Kim, Jae Weon, Kim, Byoung Gie, Kim, Sang Wun, Kim, Hee Seung, Choi, Chel Hun, Lim, Myong Cheol, YL Ngoi, Natalie, SP Tan, David, Lee, Jung-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482952/
https://www.ncbi.nlm.nih.gov/pubmed/37673858
http://dx.doi.org/10.1038/s41467-023-40829-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482952/
https://www.ncbi.nlm.nih.gov/pubmed/37673858
http://dx.doi.org/10.1038/s41467-023-40829-2

Ejemplares similares